Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from pharmacy benefit managers. The insurers are typically erecting limitations to coverage, including high expense criteria and PA t